Thalidomide-NH-PEG7 is primarily utilized in the development of PROTACs (Proteolysis Targeting Chimeras), which are innovative therapeutic agents designed to degrade specific disease-causing proteins. The compound serves as a linker that connects a target protein-binding moiety to an E3 ubiquitin ligase-recruiting moiety, facilitating the ubiquitination and subsequent degradation of the target protein by the proteasome. Its PEG7 spacer enhances solubility and flexibility, optimizing the interaction between the target protein and the ubiquitin ligase. This makes it valuable in research and drug development for conditions like cancer, neurodegenerative diseases, and autoimmune disorders, where targeted protein degradation offers a promising therapeutic strategy. Additionally, its application extends to chemical biology studies aimed at understanding protein function and regulation.